【摘要】 目的探讨阿托伐他汀强化治疗对急性冠脉综合征(ACS)患者血脂及血清超敏C-反应蛋白(hs-CRP)、基质金属蛋白酶-9(MMP-9)水平的影响。方法选取本院治疗的131例行冠脉介入治疗(PCI)的ACS患者,随机分为2组:常规组63例,采用阿托伐他汀常规治疗方案;强化组68例,采用阿托伐他汀强化治疗方案。治疗4周后,记录2组治疗前后血脂、hsCRP、MMP-9水平变化及不良反应发生情况。至随访截止,观察2组预后情况。结果治疗4周后,强化组总胆固醇、甘油三酯、低密度脂蛋白、hs-CRP、MMP-9水平显著低于治疗前及常规组(P<0.05或P<0.01),高密度脂蛋白显著高于治疗前及常规组(P<0.01)。常规组未见明显不良反应,而强化组不良反应轻微,患者耐受性好。至随访结束,强化组预后情况显著优于常规组(P<0.05)。结论与常规治疗相比,阿托伐他汀强化治疗ACS的疗效更优,能显著提高患者的临床获益。更多还原

【Abstract】 Objective To explore the influence of atorvastatin intensive treatment on blood lipid and the level of serum high-sensitivity C-reactive protein( hs-CRP) and matrix metalloproteinase( MMP-9) in patients with acute coronary syndrome( ACS). Methods A total of 131 patients with ACS performed with percutaneous coronary intervention( PCI) in our hospital were selected and randomly divided into 2 groups,namely conventional group( 63 cases) and intensive group( 68 cases).Conventional group was given atorvastatin conventional treatment while intensive group was given atorvastatin intensive treatment. After 4 weeks,the level of blood lipid hs-CRP and MMP-9 and the occurrence of adverse reactions were recorded and the conditions of prognosis were observed. Results After4 weeks,the levels of total cholesterol,triglyceride,low density lipoprotein,hs-CRP and MMP-9 in intensive group were lower than treatment before and control group( P < 0. 05,or P < 0. 01). Highdensity lipoprotein was significantly higher than treatment before and conventional group( P < 0. 01).There was no adverse reactions in conventional group but slighter in intensive group,with good tolerance. At the end of the follow-up,the prognosis of intensive group was superior to conventional group( P <0.05). Conclusion Compared with conventional treatment,atorvastatin intensive treatment has an better effect on ACS,capable of obviously improving the clinical benefit of patients.更多还原